Agenus Inc
AGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$304.82M
Close$
$-6.07
186.7% downside
Current Fair Value
186.7% downsideOvervalued by 186.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $304.82 Million |
|---|---|
| Enterprise Value | $326.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 1.55 |
| Outstanding Shares | 41,338,000 |
Return
| Return on Equity | -134.80% |
|---|---|
| Return on Assets | 53.60% |
| Return on Invested Capital | -199.27% |
Valuation & Multiples
| P/E Ratio | 2.7 |
|---|---|
| PEG | -2.7 |
| Price to Sales | 2.33 |
| Price to Book Ratio | -3.5 |
| Enterprise Value to Revenue | 2.46 |
| Enterprise Value to EBIT | 2.77 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -0.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$0.05
Average shareholder expectationRevenue Estimate
$34.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$35.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 41.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.59%▼ 14.69% |
|---|---|
| Total Invested | $11.13M▼ 63.80% |
| Investors Holding | 32▼ 58.00% |
ESG Score
No data
About Agenus Inc
CEO: Garo Armen Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , pa...